Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IMPL Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Impel Pharmaceuticals Stock (NASDAQ:IMPL) 30 days 90 days 365 days Advanced Chart Ad The Oxford ClubDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...Click here now to claim your FREE copy of Marc's AI playbook. Get Impel Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.04▼$0.8452-Week Range N/AVolume720,000 shsAverage Volume682,655 shsMarket Capitalization$956,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.Read More… Don't Pay a Dime for Marc Lichtenfeld's Top AI Picks (Ad)Usually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...Click here now to claim your FREE copy of Marc's AI playbook. Receive IMPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IMPL Stock News HeadlinesImexpharm achieves net revenue of US$39.74 million in 2024H1July 26, 2024 | msn.comCompliant Marketing In The Pharmaceutical Industry's Regulatory MazeMay 17, 2024 | forbes.comDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...October 8, 2024 | The Oxford Club (Ad)Impel Pharmaceuticals Inc. (IMPLQ)March 13, 2024 | finance.yahoo.comImpel Pharma Mulls Sale, Signs Stalking Horse Deal; Files For Chapter 11 ProtectionDecember 20, 2023 | markets.businessinsider.comImpel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate SaleDecember 20, 2023 | finance.yahoo.comAdrian Adams steps down as CEO of Seattle's Impel PharmaceuticalsNovember 6, 2023 | bizjournals.comAnalysts Offer Insights on Healthcare Companies: Impel Pharmaceuticals (IMPL) and Relay Therapeutics (RLAY)October 9, 2023 | markets.businessinsider.comSee More Headlines IMPL Stock Analysis - Frequently Asked Questions How were Impel Pharmaceuticals' earnings last quarter? Impel Pharmaceuticals Inc. (NASDAQ:IMPL) announced its quarterly earnings results on Monday, November, 15th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.42. The business had revenue of $0.09 million for the quarter. When did Impel Pharmaceuticals IPO? Impel Pharmaceuticals (IMPL) raised $80 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO. Company Calendar Last Earnings11/15/2021Today10/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMPL CUSIPN/A CIK1445499 Webwww.Impelnp.com Phone206-568-1466FaxN/AEmployees160Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,310,000.00 Net Margins-353.93% Pretax Margin-353.93% Return on EquityN/A Return on Assets-127.43% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.13 Sales & Book Value Annual Sales$20.99 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.86) per share Price / BookN/AMiscellaneous Outstanding Shares23,900,000Free Float22,418,000Market Cap$956,000.00 OptionableNot Optionable Beta1.17 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:IMPL) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredKamala’s tax plan is worse than you think—find out whyBuffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredThe most important AI company you've never heard ofBecause this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, G...Manward Press | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredOne of the largest copper discoveries in CanadaIn the electrification era, where copper and nickel are the new gold, a junior explorer is sitting on massive ...PTX Metals | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Impel Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Impel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.